AI Powered Market News

Wednesday, December 24, 2025

Menu

Trending

Topic Intelligence: obesity

Last updated: 2025-12-24 00:13:35 ET

Overall Topic Sentiment (Range Avg): Optimistic 33.3

Mentions (24h)

2

vs prior 24h: +100.0%

Mentions (Range)

3

8 day range (Dec 17 - Dec 24)

Sentiment (Avg / Median)

33.3 / 0.0

Based on 3 articles in range

Sentiment Mix (Range)

33% 67% 0%

Coverage Z-Score

+0.88

24h mentions vs 90d baseline

Topic Share of Voice (History)

Top Sources (Range)

Mentions by Hour (24h ET)

Related Co-Topics (Range)

pill (3) eli (2) lilly (2) novo (2) nordisk (2) shouldn (1) sweat (1) rival (1) having (1) fda (1) approves (1) glp (1) wegovy (1) maker (1) approval (1) helps (1) maintain (1) weight (1) loss (1) patients (1)

Latest Articles on "obesity" (Range)

CNBC Top Stories • 6h ago

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Club holding Lilly stock slumped 1% Tuesday while Novo Nordisk shares jumped nearly 9%.

Strong Bullish 100.0

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

CNBC Business • 23h ago

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.

Neutral 0.0

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

CNBC Business • 5d ago

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.

Neutral 0.0

Fraywire Market Portal, Breaking Metrics Newsletter, and Glideslope AI are designed for informational purposes only. The content provided across these platforms—including, but not limited to, stock and crypto watchlists, price tracking, trade tracking, sentiment analysis, and news articles—should not be construed as financial advice or research reports. Users are encouraged to conduct their own research and consult with qualified financial professionals before making any investment decisions. While we strive to ensure the accuracy, completeness, and reliability of the information provided, Fraywire, Breaking Metrics, and Glideslope AI make no guarantees or warranties regarding the content's validity. By using these platforms, you acknowledge and agree that you are solely responsible for your own investment decisions and actions. Fraywire, Breaking Metrics, and Glideslope AI shall not be held liable for any losses or damages resulting from the use of the information provided.

Get Connected

Fraywire & Glideslope AI are Breaking Metrics productions.
Contact the developer for advertising opportunities, questions, and more at roy@rmahd.com

○ Subscribe
○ Fraywire+
○ Glideslope AI
○ Blog
○ RMAHD
○ Merch!